Validation testing in thorough QT/QTc clinical trials

被引:12
|
作者
Tsong, Yi [1 ]
Zhong, Jinglin [1 ]
Chen, Wen Jen [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Off Biostat Off Translat Sci, Silver Spring, MD 20993 USA
关键词
assay sensitivity; controlling type I error rate; QT prolongation; statistical testing;
D O I
10.1080/10543400801995486
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In order to validate the results of a thorough QT/QTc (the duration of depolarization and repolarization of ventricles or the duration corrected for heart rate) clinical trial, ICH E14 recommended to include a concurrent positive control treatment in the trial. It further recommended that validation is achieved if the positive control has an effect on the mean QT/QTc interval of about 5ms. Zhang (2008) discussed the intersection-union test approach for testing the validation hypotheses and an alternative global average test approach. In this article, we further discuss the difference and relationship of the two sets of hypotheses and the difference in the efficiencies of the two approaches. We conclude that validation can be achieved if either one test rejects the null hypotheses without inflating the family-wise Type I error rate. However, using both approaches may improve the efficiency in validation assessment.
引用
收藏
页码:529 / 541
页数:13
相关论文
共 50 条
  • [41] Absence of QTc Prolongation with Buprenorphine/Samidorphan Combination: A Thorough QT/QTc (tQT) Study in Healthy Volunteers
    Lu, Hong
    Hard, Marjie
    Kleiman, Robert
    Liu, Wenlei
    Bergsma, Tim
    Stanford, Arielle D.
    Nangia, Narinder
    von Moltke, Lisa
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S141 - S142
  • [42] Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study
    Hulhoven, Reginald
    Rosillon, Dominique
    Letiexhe, Michel
    Meeus, Marie-Anne
    Daoust, Agnes
    Stockis, Armel
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (11) : 1011 - 1017
  • [43] CONFIRMATION OF QT PROLONGATION BY ORAL MOXIFLOXACIN IN HEALTHY JAPANESE SUBJECTS FOR THOROUGH QT/QTC STUDIES IN JAPAN
    Kumagai, Y.
    Ikeda, Y.
    Fujita, T.
    Sahashi, K.
    Saikawa, T.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 102 - 102
  • [44] Comparison of Two Methods of Estimating Reader Variability in QT Interval Measurements in Thorough QT/QTc Studies
    Salvi, Vaibhav
    Karnad, Dilip R.
    Kerkar, Vaibhav
    Panicker, Gopi Krishna
    Natekar, Mili
    Kothari, Snehal
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2014, 19 (02) : 182 - 189
  • [45] The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies
    Bouvy, J. C.
    Koopmanschap, M. A.
    Shah, R. R.
    Schellekens, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 281 - 288
  • [46] Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study
    Réginald Hulhoven
    Dominique Rosillon
    Michel Letiexhe
    Marie-Anne Meeus
    Agnès Daoust
    Armel Stockis
    European Journal of Clinical Pharmacology, 2007, 63 : 1011 - 1017
  • [47] A flexible class of models for data arising from a 'thorough QT/QTc study'
    Anand, Suraj P.
    Ghosh, Sujit K.
    PHARMACEUTICAL STATISTICS, 2011, 10 (02) : 122 - 127
  • [48] Impact of Electrocardiographic Data Quality on Moxifloxacin Response in Thorough QT/QTc Studies
    Johannesen, Lars
    Garnett, Christine
    Malik, Marek
    DRUG SAFETY, 2014, 37 (03) : 183 - 189
  • [49] Impact of Electrocardiographic Data Quality on Moxifloxacin Response in Thorough QT/QTc Studies
    Lars Johannesen
    Christine Garnett
    Marek Malik
    Drug Safety, 2014, 37 : 183 - 189
  • [50] No clinically relevant QTc prolongation with cagrilintide: a thorough QT study in healthy participants
    Gabe, M. B. N.
    Fuhr, R.
    Sinn, A.
    Eliasen, A.
    Berthelsen, K. K.
    Kuhlman, A. B.
    Baekdal, T. A.
    Nejad, A. B.
    DIABETOLOGIA, 2024, 67 : S274 - S274